Nexalin Technology, Inc. (NXL) shares are declining more than 33 percent on Friday morning trade. The shares started to trend down after reaching 1.50 Thursday after the company announced approval for its Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency.
Currently, shares are at $0.91, down 33.81 percent from the previous close of $1.38 on a volume 2,149,253.
For comments and feedback: editorial@rttnews.com